Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
188.97
-1.23 (-0.65%)
At close: Dec 31, 2025, 4:00 PM EST
189.07
+0.10 (0.05%)
After-hours: Dec 31, 2025, 5:25 PM EST
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $239.33, which forecasts a 26.65% increase in the stock price over the next year. The lowest target is $220 and the highest is $270.
Price Target: $239.33 (+26.65%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 4 | 4 | 4 | 4 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $234 → $235 | Buy | Maintains | $234 → $235 | +24.36% | Dec 10, 2025 |
| Stifel | Stifel | Strong Buy Maintains $220 → $230 | Strong Buy | Maintains | $220 → $230 | +21.71% | Dec 10, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $270 | Strong Buy | Initiates | $270 | +42.88% | Dec 9, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $185 → $234 | Buy | Maintains | $185 → $234 | +23.83% | Nov 10, 2025 |
| Benchmark | Benchmark | Strong Buy Maintains $175 → $220 | Strong Buy | Maintains | $175 → $220 | +16.42% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
255.49M
from 167.13M
Increased by 52.87%
Revenue Next Year
270.99M
from 255.49M
Increased by 6.07%
EPS This Year
7.46
from -0.22
EPS Next Year
8.41
from 7.46
Increased by 12.81%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 276.8M | 291.9M | ||||
| Avg | 255.5M | 271.0M | ||||
| Low | 226.5M | 252.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 65.6% | 14.3% | ||||
| Avg | 52.9% | 6.1% | ||||
| Low | 35.5% | -1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 8.06 | 9.31 | ||||
| Avg | 7.46 | 8.41 | ||||
| Low | 5.38 | 7.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 24.9% | ||||
| Avg | - | 12.8% | ||||
| Low | - | -2.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.